Tyra Biosciences, Inc. (TYRA): Cash & Equivalents
$77.39M
As of 2025-12-31
$73.83M
As of 2026-06-30
-32.5%
3-year compound annual growth
+38.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.39M | -15.9% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $91.97M | +58.5% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $58.01M | -76.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $251.21M | -16.9% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $302.18M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | $15.22M | n/a | 2022-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $77.39M | -15.9% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $32.30M | -13.3% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $62.41M | +84.7% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $15.12M | -65.8% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $43.76M | +18.5% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $162.05M | +227.4% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Neurogene Inc. (NGNE) | 2025-12-31 | $103.84M | -24.0% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $75.60M | +244.5% |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗